Does night work increase the risk of breast cancer? A systematic review and meta-analysis of epidemiological studies.
Yijun Jia, Yunshu Lu, Kejin Wu...
https://pubmed.ncbi.nlm.nih.gov/23403128/Actively Recruiting
Led by Oregon State University · Updated on 2025-05-02
60
Participants Needed
1
Research Sites
15 weeks
Total Duration
Researchers are evaluating a personalized telehealth program called SWISH, designed to improve sleep health in night shift nurses who suffer from insomnia related to their shift work schedules. This pilot study focuses on a behavioral therapy adapted for the unique sleep challenges faced by shift workers, aiming to improve both sleep and wake health. Participants will be randomized to receive either the SWISH intervention or delayed treatment control in a double-blind design. The SWISH intervention consists of cognitive behavioral therapy for insomnia, delivered individually via telehealth over approximately nine weekly sessions lasting 15 to 60 minutes each. Participants in the control group will complete weekly assessments without active treatment during the delay period but will be offered the SWISH therapy afterward. The therapy is provided by trained behavioral sleep medicine professionals through remote sessions. During the study, participants will take part in assessments at baseline and after about 12 weeks, measuring sleep disturbances, sleep-related impairment, fatigue, sleepiness, emotional distress, cognition, and adherence to the intervention. Researchers will track session attendance, retention rates, and participant feedback on the interventions acceptability. The total participation includes the treatment period and follow-up assessments to evaluate the interventions implementation and effects on sleep health.
CONDITIONS
Shift Worker Intervention for Sleep Health
J
Jessica R Dietch, PhD
L
Liudmyla Kozii, MD, MPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Oregon State University
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | SWISH (CBT‑I via telehealth) | WLC (no intervention) | Current guideline practice |
|---|---|---|---|
| What it is | A multicomponent behavioral intervention based on cognitive behavioral therapy for insomnia (CBT‑I), delivered individually via telehealth across nine weekly sessions | A no‑intervention wait‑list control condition | Guideline‑recommended strategies include non‑pharmacological measures such as CBT‑I, scheduled light exposure, planned napping, caffeine timing, and sleep hygiene tailored to shift work |
| Role in trial | Investigational active behavioral treatment delivered in one condition of the crossover design | Reference condition with no behavioral intervention during that segment | Represents non‑pharmacological approaches commonly recommended for shift work sleep disorder symptoms |
| Primary intended use | To reduce sleep disturbance and impairment in shift workers with insomnia via structured telehealth CBT‑I | Serves as comparator to assess effect of SWISH intervention | Manage insomnia and excessive sleepiness in shift work using behavioral and environmental strategies |
| How it is performed | Delivered individually via telehealth in nine weekly sessions of 15–60 minutes each | Participants remain on wait‑list with no active behavioral sessions during control periods | Includes scheduled light exposure during night shift, planned naps before or during shift, timing of caffeine intake, and sleep scheduling education |
| Evidence status | Effectiveness under evaluation; trial outcomes will include sleep impairment and implementation metrics | Serves as comparator to quantify change with SWISH; not intended to improve sleep on its own | Some evidence supports CBT‑I and behavioral strategies for shift workers but with modest and variable effects; efficacy still under study |
| Important risks | Behavioral intervention has no known physical risks beyond potential discomfort from discussing sleep problems | No intervention carries no procedural risk | Generally low‑risk behavioral and environmental strategies, though bright light or caffeine may disrupt circadian rhythms if improperly timed |
| Important limitations | Trial is small (n≈60), limited to nursing staff, crossover may involve carry‑over effects, and outcomes focused on attendance and PROMIS‑measured change—not long‑term clinical endpoints | As a no‑intervention condition, it does not reflect usual care and may not indicate external natural change or placebo effect | Guideline recommendations are conditional with low to moderate certainty evidence; shift work schedules make consistent implementation challenging |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - Approximately 9 weeks
Participants receive SWISH, a multicomponent behavioral intervention based on cognitive behavioral therapy for insomnia, administered individually via telehealth across approximately weekly sessions, each lasting 15-60 minutes.
Weekly telehealth sessions for approximately 9 weeks
Duration - Up to 3 weeks after treatment
Participants complete assessments after treatment to evaluate sleep health and related outcomes.
1 post-treatment assessment visit (remote or in-person)
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Yijun Jia, Yunshu Lu, Kejin Wu...
https://pubmed.ncbi.nlm.nih.gov/23403128/K A Lee
https://pubmed.ncbi.nlm.nih.gov/1475563/M S Hallbeck, B R Lowndes, J Bingener...
https://pubmed.ncbi.nlm.nih.gov/28166893/Erin A Koffel, Jonathan B Koffel, Philip R Gehrman
https://pubmed.ncbi.nlm.nih.gov/24931811/M W Johns
https://pubmed.ncbi.nlm.nih.gov/1798888/Katharine Ker, Philip James Edwards, Lambert M Felix...
https://pubmed.ncbi.nlm.nih.gov/20464765/L B Krupp, N G LaRocca, J Muir-Nash...
https://pubmed.ncbi.nlm.nih.gov/2803071/Paula K Schweitzer, Angela C Randazzo, Kara Stone...
https://pubmed.ncbi.nlm.nih.gov/16453980/Sergio Garbarino, Barbara Mascialino, Maria Antonietta Penco...
https://pubmed.ncbi.nlm.nih.gov/15586782/Dapang Rao, Haifeng Yu, Yu Bai...
https://pubmed.ncbi.nlm.nih.gov/26491356/Oregon State University
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor